A phase IIb trial in systemic lupus erythematosus reported that low-dose IL-2 restored regulatory T cells in a dose-dependent manner, according to findings published in Nature Communications. The study supports IL-2 as a mechanism to rebalance immune regulation rather than broadly suppress inflammation. The results focus on Treg recovery using low-dose regimens, aiming to improve immune tolerance while avoiding the safety tradeoffs that have constrained higher-dose approaches historically. For biotech developers, the trial adds another dataset to the expanding lupus pipeline centered on immune modulation through more precise pathway targeting.